Habib Scientific Office has earned the trust of families across Egypt by providing superior quality prescription and consumer healthcare products since 1983. Guided by a passion for excellence and a commitment to quality, Habib Scientific Office is fiercely determined to continue to deliver the most effective products in their purest form to their loyal customers.
The Habib Scientific Office established the Marcyrl Import and Export Company in 1998, and in 2002 construction of the Marcyrl Pharmaceutical Industries manufacturing plant began.
From the beginning, the company was planned to formulate dosage forms of recently generic drugs from local and imported intermediates, applying the latest GMP regulations throughout the operational or line departments beginning with evaluation of raw materials, calibration of equipment’s and control, holding and distribution of finished products to assure quality, effectiveness and safety.
Marcyrl production is covering the following major dosage forms :
Marcyrl’s Vision is to be one of the largest leading Pharmaceutical Companies in Egypt, and to establish a strong presence in markets around the world.
Contact
Habib Scientific Office
Buildings Sheraton, Square No.1227, Building No. 8C, Cairo – EGYPT
Tel: +2 02 22678596 & +2 02 22678597
Fax: +2 02 22660905
Marcyrl Pharmaceutical Industries
El Obour City, The West Extension, Block 20005, Cairo – EGYPT
Tel: +2 02 46651641 & +2 02 46651642
Fax: +2 02 46651650
The latest news from Egyptian healthcare and life sciences, including progress towards the launch of a massive new oncology hospital, why local manufacturer EIPICO is expanding into Kazakhstan, increased governmental…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
See our Cookie Privacy Policy Here
